Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Incretin‐based therapies have a glucose‐dependent mode of action that results in excellent glucose‐lowering efficacy with very low risk of hypoglycaemia, and weight neutrality [dipeptidyl peptidase‐4 (DPP‐4) inhibitors] or weight loss [glucagon‐like peptide‐1 (GLP‐1) receptor agonists], in people with type 2 diabetes mellitus (T2DM). Patient‐reported outcomes (PROs) complement physician evaluations of efficacy and tolerability and offer insights into the subjective experience of using modern diabetes treatments. We conducted a systematic search of clinical trials of the GLP‐1 receptor agonists liraglutide, exenatide and long‐acting exenatide, one of which included the oral DPP‐4 inhibitor sitagliptin as a comparator. No other PRO data for DPP‐4 inhibitors were identified. This review summarizes PRO data from eight clinical trials, the majority of which used the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and/or Impact of Weight on Quality of Life‐Lite (IWQOL‐Lite) to evaluate patient experience. People with T2DM were highly satisfied with modern incretin‐based therapies compared with traditional therapies. Treatment satisfaction (including perceptions of convenience and flexibility) was high and generally higher with GLP‐1 agonists in association with their greater glucose‐lowering efficacy and tendency to facilitate weight loss. Weight‐related quality of life (QoL) also improved in people using incretin therapies. The glycaemic improvements achieved with GLP‐1 receptor agonists, coupled with the low incidence of hypoglycaemia and ability to cause weight loss, seemed to offset potential concern about injections. It is plausible that superior patient‐reported benefits found in clinical trials may translate into improved, clinically meaningful, long‐term outcomes through increased treatment acceptability. Long‐term, prospective data are needed to ascertain whether this is the case in practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 2×
“8 mg, once daily) with exenatide (10 μg twice daily), both as add-on to metformin and/or SUs, in the first head-to-head trial of the two approved GLP-1 receptor agonists [49]; this was followed by a nonrandomized extension phase in which all participants used liraglutide 1.”
BackgroundMethodNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“Participants with elevated HbA1c using OADs were randomized to exenatide once weekly or twice daily for 30 weeks in the DURATION-1 study, after which the twice-daily group switched to the once-weekly formulation for a further 22 weeks [69].”
MethodGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Development of a brief measure to assess quality of life in obesity
Kolotkin, R. L., Crosby, R. D., Kosloski, K. D., & Williams, G. R. (2001) · Obesity Research · doi:10.1038/oby.2001.13 · Cited by 641
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Nguyen, N. T., Nguyen, X.-M. T., Lane, J., & Wang, P. (2011) · Obesity Surgery · doi:10.1007/s11695-010-0335-4 · Cited by 385
Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
Stephens, J., & Edavalath, M. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s6358 · Cited by 17 · cited 4×
“The 26-week, open-label, LEAD-6 study (n = 464) compared liraglutide (1.8 mg, once daily) with exenatide (10 μg twice daily), both as add-on to metformin and/or SUs, in the first head-to-head trial of the two approved GLP-1 receptor agonists [49]; this was followed by a nonrandomized extension phase in which all parti…”
BackgroundInfluential
Cited by
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
GLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“However, due to the high level of motivation for weight loss among the patient population, subcutaneous administration seems to be acceptable for most subjects who seek to lose weight [86].”
BackgroundEffects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Di Folco, U., Vallecorsa, N., Nardone, M. R., Pantano, A. L., & Tubili, C. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01936-6 · Cited by 29
Metadata
- Authors
- Davies, M., & Speight, J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-04-17
- Volume
- 14
- Issue
- 10
- Pages
- 882-892
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2123850120
- Cited by
- 54
- References
- 9
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01595.x
- The paper
- Davies, M., & Speight, J. (2012). Patient‐reported outcomes in trials of incretin‐based therapies in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01595.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.